ATEC Reports Third Quarter Financial Results
Business Wire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $221 million, up 13% year-over-year
- ➤2026 revenue outlook approximately $862 million, including $789 million surgical revenue
- ➤2026 adjusted EBITDA outlook approximately $137 million
- ➤Surgical hardware revenue $26 million, up 17% year-over-year
- ➤Biologics attachment underperformed expectations; improving performance is a priority
Expert Statements
Pat Miles, Chairman and Chief Executive Officer of Alphatec Holdings
“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment. We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us. At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%. These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem. The disciplined execution of biologics is required to realize full procedural revenue translation, while building the foundation for the longer-term opportunity with OsteoAdapt (Theradaptive). We remain bullish on our ability to make continued progress toward increasingly profitable growth.”
Case volumes grew 20% and net new surgeon users increased 25%
Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2026, and business highlights.
Get started
Create a free account to read the full story.